When will aimovig become generic?

When does Aimovig’s exclusivity end (and when could a generic arrive)?

Aimovig (erenumab-aooe) is still under patent protection, so a generic version can’t launch until the relevant patents and any additional exclusivity periods expire. The exact “generic date” depends on which patent(s) control the drug product and whether exclusivity extensions apply.

For the most up-to-date patent-expiration timing and key controlling patents for Aimovig, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/aimovig

Is Aimovig guaranteed to become “generic,” or could biosimilars arrive first?

Because Aimovig is a biologic (a monoclonal antibody), the practical path to competition is usually a biosimilar—not a traditional small-molecule generic. Even if a “generic” is what many people call it, the likely future products are biosimilars approved under the Biologics Price Competition and Innovation Act (BPCIA).

What would you look for to know it’s near the launch date?

You typically see timing signals through:
- Patent listings expiring (the controlling patents that prevent launch)
- Biosimilar development announcements
- FDA approval signals for biosimilars (approval doesn’t always mean immediate market entry due to patent litigation)

DrugPatentWatch tracks the patent landscape that determines when competitors can pursue or launch, including dates tied to specific patents: https://www.drugpatentwatch.com/p/aimovig

Why the “generic date” can be different from the “first possible entry” date

Even after some patents expire, the FDA/market entry date can shift because:
- Other patents may still be listed and blocking launch
- Patent litigation can delay launches even if some expiration dates have passed
- Exclusivity periods (if applicable) can extend the window beyond the earliest patent expiration

DrugPatentWatch is the most direct place to map the controlling patents to those timelines: https://www.drugpatentwatch.com/p/aimovig

Sources

1. https://www.drugpatentwatch.com/p/aimovig